NASDAQ: TCRXTscan Therapeutics Inc Stock
$1.61+0.02 (+1.26%)
Updated Apr 30, 2025
TCRX Price
$1.61
Fair Value Price
-$0.86
Market Cap
$90.83M
52 Week Low
$1.02
52 Week High
$9.69
P/E
-1.41x
P/B
0.38x
P/S
120.9x
PEG
N/A
Dividend Yield
N/A
Revenue
$2.82M
Earnings
-$127.50M
Gross Margin
100%
Operating Margin
-4,397.94%
Profit Margin
-4,527.7%
Debt to Equity
0.54
Operating Cash Flow
-$111M
Beta
0.67
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
TCRX Overview
TScan Therapeutics Incorporated is a preclinical-stage biopharmaceutical company developing T cell receptor-engineered therapies for the treatment of cancer. TSC-100 and TSC-101 are intended to treat patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. TSC-200, TSC-201, TSC-202, TSC-203, and TSC-204 are intended to treat solid tumors.The company was incorporated in 2018 and is headquartered in Waltham, MA.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine TCRX's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More
Zen Rating Component Grades
B
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
TCRX
Ranked#114 of 462
Ranked#114 of 462
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $3.07 | A | |
| $8.24 | A | |
| $24.29 | A |
Be the first to know about important TCRX news, forecast changes, insider trades & much more!
TCRX News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how TCRX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
TCRX ($1.61) is overvalued by 285.83% relative to our estimate of its Fair Value price of -$0.86 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
TCRX ($1.61) is not significantly undervalued (285.83%) relative to our estimate of its Fair Value price of -$0.86 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
TCRX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more TCRX due diligence checks available for Premium users.
Valuation
TCRX fair value
Fair Value of TCRX stock based on Discounted Cash Flow (DCF)
Price
$1.61
Fair Value
-$0.86
Undervalued by
286.41%
TCRX ($1.61) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
TCRX ($1.61) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
TCRX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
TCRX price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-1.41x
Industry
-162.28x
Market
29.18x
TCRX price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.38x
Industry
4.45x
TCRX is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
TCRX's financial health
Profit margin
Revenue
$665.0k
Net Income
-$35.8M
Profit Margin
-5,384.8%
TCRX's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
TCRX's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$371.1M
Liabilities
$130.1M
Debt to equity
0.54
TCRX's short-term assets ($292.72M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
TCRX's short-term assets ($292.72M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
TCRX's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
TCRX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$27.4M
Investing
$27.3M
Financing
$45.7M
TCRX's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
TCRX vs Biotech Stocks
Tscan Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.